Abbvie

This study tests whether the drug upadacitinib, taken with a steroid taper, can prevent flare-ups in people with Takayasu arteritis—a rare disease that causes inflammation in large blood vessels. About 56 adults who have had a recent relapse despite steroid treatment will take ei…

This study tests a new drug called TNB-383B in people with multiple myeloma that has come back or not responded to at least three prior treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to find the safest dose and see how well it c…

This study tests a daily pill called upadacitinib to see if it can safely bring back skin color in people with non-segmental vitiligo, a condition where the immune system attacks pigment cells. About 540 adults and teens will take either the drug or a placebo for 48 weeks, then e…

This study looks at how well the drug foslevodopa-foscarbidopa works for people with advanced Parkinson's disease in everyday medical practice. About 250 adults in France who are already prescribed this drug by their doctor will take part. Researchers will track their quality of …

This study tests whether a daily pill called upadacitinib, when used with steroid creams, can safely reduce eczema symptoms like itching and skin redness in teens and adults with moderate to severe disease. About 1,500 participants took the drug or a placebo for 16 weeks. The mai…

This study follows about 100 adults with acute myeloid leukemia (AML) in Israel who are already prescribed venetoclax by their doctors. Researchers will track how long patients live, how many achieve remission, and what side effects occur in routine practice. The goal is to see i…

This study looks at how well the medication upadacitinib (RINVOQ) controls moderate to severe eczema (atopic dermatitis) over two years in everyday medical practice. About 634 teenagers and adults in Germany will be observed after starting the drug as prescribed by their doctor. …

This study tests whether a daily pill called upadacitinib can help adults with Crohn's disease stay in remission and avoid flare-ups over the long term. About 747 people who already responded to the drug in earlier studies will either continue taking it or switch to a placebo. Th…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The goal is to track long-term safety and side effects. About 165 adults are taking part, and they must continue to tolerate the drug well.

This program offers early access to the investigational drug ABBV-787 for people with acute myeloid leukemia who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefits outweigh the risks. The drug is not ye…

This study tests a new drug called ABBV-400 combined with standard chemotherapy and targeted therapy for adults with advanced colorectal cancer that cannot be removed by surgery. About 280 participants will receive different doses to find the safest and most effective combination…

This phase 3 study tests whether upadacitinib, a drug already approved for other autoimmune diseases, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year. The goal is to see if the treatment reduces di…

This study tests a new experimental drug called ABBV-101 in adults with certain types of blood cancers (like lymphoma and leukemia) that have returned or not responded to prior treatments. The main goals are to check the drug's safety and find the best dose. About 340 participant…

This study follows about 427 adults with advanced Parkinson's disease who are receiving ABBV-951, a medication given as a continuous shot under the skin. The goal is to see how well it controls symptoms like tremors and stiffness over roughly 3 years in real-world settings. Parti…

This early-phase study tests an investigational drug called ABBV-400 in about 520 adults with advanced solid tumors, including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose, either alone or combined with another drug (bevacizumab). …

This phase 3 study tests whether adding venetoclax to standard azacitidine helps people with newly diagnosed, higher-risk myelodysplastic syndrome (MDS) live longer. About 500 adults worldwide will receive either the combination or azacitidine alone. The main goal is to see if th…

This program offers early access to telisotuzumab vedotin for people with non-small cell lung cancer who have no other suitable treatments and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by regulato…

This early-phase study tests a new drug called IMGN151 in 256 adults with recurrent gynaecological cancers (ovarian, endometrial, cervical, and related cancers). The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to check safety, f…

This study looks at adults with diabetic macular edema (DME) whose vision hasn't improved enough with standard anti-VEGF injections. They receive a dexamethasone implant (DEX-I) that slowly releases steroid into the eye. Researchers will track how many extra anti-VEGF shots they …

This early-stage study tests a new drug called ABBV-525 in people with B-cell cancers like lymphoma and leukemia. The goal is to find a safe dose and see if it can shrink tumors. About 78 adults will take the drug by mouth at different doses over several months.

This early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 pa…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …

This study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. Currently, patients need frequent eye injections to control the disease. The trial aims to see if RGX-314 can provide similar or be…

This study tests an experimental drug called lutikizumab for people with moderate to severe ulcerative colitis, a condition causing colon inflammation and bleeding. About 200 adults will receive either lutikizumab or the standard drug adalimumab for up to 52 weeks to see which wo…

This study tests an investigational drug called lutikizumab for adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease causing painful lumps and scars. The main part of the study includes about 160 people who have not responded to anti-TNF therapy, w…

This study tests an injectable drug called risankizumab for people with moderate to severe Crohn's disease, a condition that causes painful gut inflammation. About 276 adults will receive either the drug or a placebo for up to 24 weeks, followed by an open-label extension. The go…

This early-stage trial tests an experimental drug called etentamig combined with standard treatments for multiple myeloma, a type of blood cancer. About 320 adults whose cancer has returned or not responded to prior therapy will participate. The main goal is to find the safest do…

This study tests the drug upadacitinib (RINVOQ) in children aged 2–17 with moderate-to-severe ulcerative colitis who haven't improved with standard treatments. The trial has three parts: an 8-week open-label phase where all kids get the drug, a 44-week blinded phase comparing two…

This study tests whether risankizumab works better than the approved drug ustekinumab for adults with moderate to severe Crohn's disease who have not responded to anti-TNF therapy. About 527 participants will receive either risankizumab or ustekinumab through IV and then injectio…

This study tracks how well risankizumab works for adults recently diagnosed with moderate plaque psoriasis (within the last 2 years) who haven't tried advanced treatments before. About 250 people in Greece will receive the drug as prescribed by their doctor and be observed for up…

This early-phase study tests an experimental drug, ABBV-706, alone or with other treatments, in adults with advanced solid tumors like small cell lung cancer and brain tumors. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 288 partici…

This early-phase study tests an experimental drug called etentamig (ABBV-383) in about 55 adults with multiple myeloma that has returned or stopped responding to prior therapies. The drug is given as a shot under the skin or through an IV. The main goals are to check safety, side…

This study tests whether the oral medication upadacitinib works better than the injected adalimumab for adults with moderate-to-severe rheumatoid arthritis who have already tried and failed one TNF inhibitor. About 480 participants will be randomly assigned to receive either drug…

This phase 2 study tests a one-time gene therapy injection (RGX-314) for people with diabetic retinopathy, a leading cause of vision loss. The treatment aims to reduce the need for frequent eye injections by delivering a gene that helps control abnormal blood vessel growth. About…

This study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…

This early-phase study tests an experimental drug called cofetuzumab pelidotin in about 65 adults with a specific type of advanced lung cancer (non-small cell) that has returned after standard treatments. The drug is designed to seek out and attack cancer cells that have a protei…

This study looks at the long-term safety and effectiveness of a daily pill called upadacitinib for people with ulcerative colitis, a chronic bowel disease causing inflammation and ulcers. About 950 adults who didn't get better with earlier treatments or lost response will take th…

This study tests an experimental drug, telisotuzumab vedotin, in about 270 adults with a certain type of advanced lung cancer (c-Met+ non-small cell lung cancer) that has already been treated. The drug works like a guided missile, delivering chemotherapy directly to cancer cells …

This study tests whether adding the experimental drug navitoclax to standard therapy ruxolitinib can shrink the spleen and ease symptoms in adults with myelofibrosis, a rare bone marrow cancer. About 330 participants whose cancer returned or didn't improve after prior treatment w…

This study follows about 200 adults in Canada with acute myeloid leukemia (AML) who cannot receive intensive chemotherapy. All participants take venetoclax pills daily as part of their routine care. Researchers track survival and remission rates over 36 months to see how well the…

This study tests whether a daily pill called upadacitinib, taken along with steroid cream, can safely improve moderate to severe eczema in children aged 2 to 11 in Japan. About 99 kids will receive either the drug or a placebo for 12 weeks, then all will get the drug for up to a …

This study tests whether the drug risankizumab can help people with ulcerative colitis stay in remission (symptom-free) for up to a year. About 1,200 adults who already improved with risankizumab in an earlier study will either continue the drug or receive a placebo. The goal is …

This study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 adults will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. The goal is to see if it safely reduces skin redness…

This early-phase study tests an experimental drug called ABBV-453 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments. Participants first receive a standard antibody (obinutuzum…

This program offers early access to the investigational drug fosigotifator for people with vanishing white matter or Cree leukoencephalopathy, rare and serious brain diseases. It is not a clinical trial but a way for eligible patients to receive the drug before it is officially a…

This study tests a two-step treatment for a type of ovarian cancer that has come back after initial chemotherapy. First, patients receive a standard chemo drug (carboplatin) plus a targeted drug (mirvetuximab soravtansine) that attacks cancer cells with a specific marker (FRα). T…

This study looks at how happy people are with their face after getting JUVÉDERM fillers to fix volume loss from medical weight loss. About 75 adults who lost weight and have hollow or sagging areas in their face will receive injections. The goal is to see if the treatment improve…

This study collects safety information and patient satisfaction after using the CoolSculpting Elite device to reduce fat in the chin, inner thighs, and back/bra areas without surgery. About 102 adults with visible fat in these areas will be treated and followed. The goal is to co…

This study tests whether adding elagolix to birth control pills can reduce moderate to severe pain from endometriosis. About 800 premenopausal women with confirmed endometriosis will take either the drug combo or a placebo for 3 months, then all receive the active treatment for 1…

This study tests an injectable gel called ELAPR002f for adults with indented acne scars on the cheeks. About 157 participants will receive either the gel or a saline placebo over 2 months, then be followed for up to a year. The goal is to see if the gel safely improves the look o…

This study looks at how well the migraine medication ubrogepant helps adults in Canada return to normal activities after a migraine attack. About 167 participants will take the drug as prescribed by their doctor and be followed for up to 12 weeks. The main goal is to see how many…

This early-stage study in 9 healthy adults aims to understand how the experimental drug ABBV-932 is absorbed and processed by the body, including whether food affects its levels. Participants take the drug by mouth and provide blood samples to measure drug concentrations. The stu…

This study watches women with uterine fibroids who are already taking the drug Oriahnn for heavy bleeding. Researchers want to see how many experience hair loss, when it starts, and if it goes away. About 1,600 women will fill out questionnaires for up to 24 months. No new treatm…

This early-stage study looks at how a new drug called ABBV-295 interacts with common birth control pills in healthy women who are overweight or obese. The main goal is to check for side effects and measure drug levels in the body. About 20 women will take part to help researchers…

This study looks at how a common antifungal drug (itraconazole) changes the way ABBV-932 moves through the body. About 20 healthy adults will take both drugs and have their blood levels measured. The goal is to check safety and understand the drug interaction, not to treat any di…

This early-stage study tests a single dose of the investigational drug ABBV-701 in about 100 healthy adults from Western and Asian backgrounds. The main goal is to check for side effects and measure how the drug moves through the body. Participants receive either the drug or a pl…

This study involves 40 healthy adults to see how the experimental drug ABBV-8736 moves through the body when given as a shot under the skin compared to an infusion into a vein. Researchers will measure drug levels, safety, and side effects. The goal is to find out if the under-th…

This study looks at how two types of oral treatments for chronic lymphocytic leukemia (CLL) affect patients' well-being and quality of life. About 146 adults in Spain who are already taking these medications will fill out questionnaires over 18 months. The goal is to understand h…

This early-stage study tests a new drug called ABBV-277 in 32 healthy adults for the first time. The main goal is to check its safety and how the body processes it. Participants receive a single dose and are monitored closely. This study does not aim to treat any disease.

This study watches 110 adults with diabetic macular edema who are already prescribed OZURDEX by their doctor. Researchers will track side effects and eye health for 2 years to see how safe the treatment is in real-world use. No extra tests or treatments are required beyond normal…

This early-stage study is testing a new drug called nacresertib in 96 healthy adults to see if it is safe and how the body processes it. Participants will take either a single dose or multiple doses of the drug. The goal is to gather safety information, not to treat any disease.